Sollers College

Tag: Healthcare

  • Why Autonomous Clinical Trials are the Best Chance of Success?

    Why Autonomous Clinical Trials are the Best Chance of Success?

    An autonomous clinical trial: what is it?

    • The terms virtual, home, remote, and siteless are some of the terms used to characterize the idea of autonomous trials. Whatever name the organization decides to use, the objective remains the same: easing patient participation in clinical trials by minimizing or doing away with the need for travel to designated locations.
    • Autonomous does not entail carrying out clinical trials without the presence of medical experts. The need for direct patient interaction is eliminated, and the process is also made more efficient. Instead, it focuses on areas where sponsors and CROs can adopt a hybrid approach to clinical research by utilizing technology and other cutting-edge solutions.
    • Individuals are aware that cutting down on the time and expense needed to enroll in clinical trials helps reduce participant burden while increasing efficiency and retention rates. The decentralized system could be viewed as the pinnacle of a patient-centered clinical trial design strategy.
    • It is noteworthy that there is a spectrum of autonomous trials. Even if implementing a completely autonomous model in which patients never have to visit a clinical site isn’t feasible, adding some virtual or at-home components.
    • There will be more home-based trials as technology develops and more clinical trials successfully incorporate autonomous components; participant expectations will rise in parallel.

    The principal advantages of autonomous clinical studies

    The main objective of autonomous clinical trials is to facilitate clinical trial participation as much as possible so that participants can carry on with their daily lives with as few gaps as possible.

    STUDIES AND PROSPECTS OF AUTONOMOUS CLINICAL TRIALS

    Many prospective trial participants will be maintaining full-time positions, managing health conditions, and raising families. In such a situation, it may not only be difficult but also impossible to require patients to attend site visits, which entail hours of travel and accumulated costs.

    Clinical trial development could significantly improve through fully autonomous trials in various ways, such as:

    • Simplifying the process of finding potential volunteers will expedite the patient recruitment process. If participation was simpler, more patients would be able and willing to participate, which would ease the pressure on sponsors and CROs to find participants.
    • Improving participant diversity by allowing patients to be recruited from a larger pool as opposed to just those who live close to a participating site. This is particularly advantageous for research on rare diseases, as clinical trials frequently involve the same small number of participants.
    • Because technology allows for greater autonomy, patients become more informed, knowledgeable, and involved. Numerous studies indicate that patients who are actively involved in their care perform tasks like keeping electronic diaries more accurately and truthfully. Additionally, electronic records can be automated and validated when needed.
    • Collecting more varied and useful data sets through real-time remote patient monitoring.
    • Additionally, gathering data in an authentic environment is likely to yield insights devoid of the prejudice that arises from completing evaluations in a medical setting.
    • Better data reliability and accuracy: Gathering data with wearables, apps, and smartphones keeps data organized and secure.
    • Standardized data collection and sharing are made possible by technological advancements, making results analysis, and reporting easier.

    As far as the autonomous trial is concerned, three fundamental principles must be followed:

    Technology that is simple to use and intuitive to learn should be used for accessibility. When patients can access technology on devices, they already own and are familiar with, and when it fits seamlessly into their daily routines, clinical trials benefit greatly from its use.

    Keep things as easy as possible for patients. Should the tasks assigned to them be excessively intricate, this can lead to tension and compromise the accuracy of outcomes due to increased opportunities for mistakes.

    Ensure that your processes and tools have undergone extensive testing and that you are aware of any potential hazards that need to be mitigated. This is all part of maintaining reliability. Use patient input to make continuous improvements as the trial goes on.

    Imagine a setting where groundbreaking medical research has the potential to transform healthcare delivery and improve people’s health. Soller’s clinical research management certificate and clinical trial management courses, along with clinical trial management training, serve the dual purpose of clinical research to learn and to heal.

    The need for qualified clinical researchers is growing in the US. As medicine advances, there will be a greater need for qualified professionals who can comprehend complex clinical data.

  • An Evolution of Drug Safety Assessment with Artificial Intelligence in Drug safety

    An Evolution of Drug Safety Assessment with Artificial Intelligence in Drug safety

    First signs of artificial intelligence in drug safety assessment

    • Artificial intelligence has become a game-changing force in the healthcare industry, where accuracy and safety are crucial. This has had a profound impact on many aspects of the medical industry. 
    • The combination of artificial intelligence and pharmacovigilance is one of these, and it is a testament to how innovation can reimagine patient safety and lead to an exciting new phase of drug governance and surveillance. 

    Disclosing AI in drug safety

    • The introduction of AI in pharmacovigilance can be compared to the discovery of a potent new lens through which the safety of pharmaceuticals can be examined with unmatched depth and effectiveness.
    •  The traditional pharmacovigilance approach, which relied on human-led reporting and manual analysis, was prone to delays, human error, and the inherent limitations of the human capacity to process enormous volumes of data. 
    • This scenario paved the way for AI’s entry into the field, promising transformative improvements rather than merely incremental ones.

    The positive impacts of AI

    • At the core of AI’s incorporation into pharmacovigilance is its astounding ability to decipher complex patterns, spot correlations, and comb through enormous datasets at speeds that humans could never match. 
    • Experts in drug safety are now better able to detect subtle signals that might otherwise be lost in the noise of data overload thanks to this capability.
    • Electronic health records, social media posts, clinical trial data, and medical literature are just a few of the information sources that AI algorithms can analyze.
    •  AI can help with the early detection of adverse drug reactions (ADRs) in this way, enabling prompt intervention and risk reduction. 
    • Additionally, because AI is constantly learning, it gets better at spotting new and changing patterns, which makes its insights more valuable.

    New Developments in Signal Detection

    • The time-consuming manual review process used in the past to find signals in pharmacovigilance was frequently hampered by the sheer amount of data. 
    • On the other hand, AI-driven signal detection is distinguished by its speedy scanning of large datasets for new patterns or outliers. 
    • The algorithms can recognize sudden increases in reported adverse events that could be potential ADRs, allowing regulators and healthcare professionals to quickly investigate and take appropriate action.

    Streamlining drug safety processes

    • Beyond signal detection, AI is increasingly being incorporated into pharmacovigilance workflows.
    •  Data collection, case processing, and risk assessment are just a few of the things it streamlines. 
    • To gather pertinent information about adverse events, AI-powered chatbots, and virtual assistants can interact with healthcare providers and patients.
    •  This improves the precision and effectiveness of data collection. 
    • Automation of case processing speeds up the identification of potential safety issues and eases the workload on human resources, freeing up experts to work on more intricate tasks.
    • Predictive analytics in AI greatly aid risk assessment, a pillar of pharmacovigilance. AI can predict potential risks related to medications, patient populations, or dosages by examining historical data and identifying factors that contribute to ADRs.
    • AI has the potential to encourage proactive signal detection as well. AI systems can detect signals even before they appear as overt trends by continuously monitoring data streams, potentially halting the progression of unfavorable events.

    The Potential Advantages of AI for Drug Monitoring

    For reporting and analyzing adverse events, pharmacovigilance has traditionally relied on manual processes, which frequently cause delays and potential errors. With its ability to process enormous amounts of data, identify patterns, and offer insights that are otherwise difficult to uncover, AI is quickly changing this environment.


     Streamlined Data Evaluation: The amount of medical data that is produced every day is too much for human analysis. Electronic health records, social media, and academic medical literature are just a few of the sources of data that AI algorithms can process, both structured and unstructured.

    Real-time monitoring and potential adverse events are more easily identified thanks to this automation.

    Signal monitoring: algorithms powered by AI are incredibly good at spotting statistical anomalies and trends in sizable datasets. This skill enables early detection of possible signals related to unfavorable events, resulting in quicker assistance and response.


     Natural Language Processing (NLP): As patient-generated material on social media and healthcare discussion boards increases, valuable information frequently hides in unstructured text. With NLP techniques, AI will read this content and extract pertinent information to better understand clients experiences and concerns.

    Automated Analytics: AI can forecast potential safety issues and new trends thanks to its ability to learn from historical data. This anticipatory approach enables regulatory agencies and healthcare professionals to take proactive steps to reduce risks before they worsen.


     Drug-Drug Interaction Inspection: Artificial intelligence (AI) algorithms can evaluate possible relationships between various drugs, lowering the risk of complications brought on by drug combinations.

    Accessing Barriers and Strategies for the Future

    • AI is promising to have revolutionary effects when it comes to drug safety, but it doesn’t come without its difficulties as well. Data quality, privacy issues, as well as algorithm bias are some of the crucial factors that require close attention in the analysis. 
    • Adapting AI to the advancement of healthcare in a way that balances the ethical application of AI and the goal of advancing healthcare remains a task that needs to be accomplished.
    • AI is expected to play an increasingly important role in pharmacovigilance in the future as technology continues to develop. In the future, artificial intelligence systems may work in concert with expert humans to improve safety monitoring by leveraging each party’s strengths and exploiting what each has to offer.

    Summary

    • AI has marked a significant turning point for the pharmaceutical industry.
    • The field of pharmacovigilance will soon be able to improve patient safety in ways that were never thought to be feasible by utilizing the power of artificial intelligence to analyze enormous amounts of data and predict potential risks in a way that was previously thought to be impossible.
    • The Next Generation of Drug Safety Monitoring will standardize preventative actions and quick responses, ensuring that the benefits of medical innovation are realized as soon as they can be foreseen and without compromise.
    • A growing number of pharmaceutical companies and medical groups have started to embrace this transformation in recent years.
  • Pharmacovigilance in Preventive and Therapeutic Medicine

    Pharmacovigilance in Preventive and Therapeutic Medicine

    The importance of systematic pharmacovigilance is being gradually acknowledged by all companies. Additionally, the importance of patient-centricity is increasing, and there are more publicly available safety data as a result.

    Therefore, all businesses are increasingly aware of proactive pharmacovigilance, regardless of their size and product line-up.

    Regulations for risk management and product safety have undergone a period of significant change, with regulations in developed regions becoming stricter and those in emerging markets evolving quickly.

    The importance of emerging markets has caused a shift in the market’s geographical focus. Pharmacovigilance operations have become more complex because of alliances created between various international stakeholders, including generic producers, distributors, service providers, and technology providers.

    Additional elements that add to this complexity are the change in the ratio of small and large molecules, the shift in the therapeutic area’s focus, and the rigor required to gather safety data for new classes of products.

    Determining that all safety systems and PV practices used by an organization firmly tie into a single, truly global PV framework is crucial. This is because proactive PV depends on compliance with various regulations and guidelines. Establishing such a framework takes much more than just collecting safety information from distributors, partners, and affiliates.

    To establish a global PV strategy, a global PV system was established.

    Global Pharmacovigilance Network

    A PV system’s structure, procedures, and intended results define it. It is described as a system used by a company to carry out its legal obligations and tasks related to PV. It was created to track the security of approved pharmaceutical products and identify any changes to their risk-benefit ratio. All licensed products must be protected from adverse drug reactions (ADRs) by a strong, global system, no matter where they are licensed or where they are sold.

    There must be a strong, global system in place to record and manage adverse drug reactions for all licensed products. This is true wherever similar products are sold in the world, and wherever they are licensed in the markets. A global system must also be able to execute all downstream tasks, including regular reporting and safety surveillance.

    A company’s corporate quality system must include a global PV system as a fundamental component. It is complicated by nature and necessitates the seamless cooperation of several parties such as company divisions, such as regulatory and medical affairs, as well as commercial, corporate, customer service, and complaint intake departments, as well as the entire company’s leadership.

    Therefore, the system must consider the accountability and responsibilities of each of these entities in terms of how they directly or indirectly relate to safety. Additionally, harmonization and standardization of process workflows are essential to consider their interdependencies.

    The following crucial components are necessary for a successful global PV system, and MAHs may use specialty safety consulting and service providers who can suggest and implement them:

     

    https://sollers.college/life-science/drug-safety-and-pharmacovigilanc/

     

    There are various ways to explain the detailed PV Quality System with documented procedures.

    1. A sufficient number of knowledgeable and skilled employees is required in all areas of operations.
    2. Effective business collaborations with partners, associates, and suppliers. A few of these include contracts with suppliers and business partners, as well as the sharing of safety information.

    The PV system’s final and most important component, corporate level structure, does two things:

     1) aligns the various entities that are within its scope;

     2) makes it possible for compliance from all business units (BUs) and therapeutic areas (TAs); and 

    3) strengthens the connection between the main PV function and specific affiliates.

    The system requires responsiveness to emerging trends, including new operating structures, emerging public data sources, and providers. Effective oversight of safety-related activities across all entities in scope is also crucial.

    Developing and Planning a Global PV System Strategy

    • There are numerous challenges for organizations of all sizes when it comes to establishing a global PV system, regardless of the type of organization.
    • The risk of non-compliance and the lack of internal availability of safety expertise may be a significant challenge for a small business with a finite number of products.
    • The number of distributors and business partners, as well as the manufacturer’s focus and diligence on product safety, may present the biggest difficulties.
    • The most significant challenges for large businesses with a diverse product mix and extensive global reach may be ensuring consistent worldwide SOPs for safety and risk management across product categories and regions, as well as efficient oversight of all parties.
    • The foundation for establishing an efficient system is a carefully thought-out strategy that considers both the organization’s short- and long-term business plans.
    • There must be a thorough examination of the present situation and an analysis of the gaps in terms of people, procedures, and technology.
    • A thorough understanding of the various regulatory requirements, as well as the global organizational structure and operating model necessary to enable the crucial level of oversight and control, is required. An ideal framework for setting up a successful global PV system will be created.
    • A comprehensive understanding of safety laws and international business practices will be utilized to develop a strategic plan.

    Synopsis

    Globalization of the economy and the impact of cutting-edge technologies on healthcare delivery will present significant challenges and opportunities for life sciences decision-makers. Medical knowledge, techniques for its analysis, and emerging sources of knowledge are transforming the current reactive system into a proactive one.

     Globally, regulations are also changing to take a more proactive stance, but they still tend to be too procedure-focused, which frequently stifles innovation. Furthermore, the technical resources necessary for a successful benefit-risk analysis are still in the early stages of development.

     All safety systems and PV practices must be tightly integrated into a truly global PV framework for organizations to succeed in the current environment.

    An approach that considers all relevant factors is required to set up such a framework. This system considers the responsibility and commitments of all entities, and how they relate to safety.

    Our mission at Sollers College is to provide students with the fundamental information and practical skills to meet the demands of the rapidly expanding healthcare, life science, and pharmacovigilance fields. 

    Graduates from Sollers will advance into rewarding careers with leading international corporations. 

    To learn how we can assist you in formulating your future, call or drop by today.

     

  • Drug safety case processing: key issues and strategies to prevent them

    Drug safety case processing: key issues and strategies to prevent them

    Case processing is one of the most crucial aspects of drug safety. It provides data for the analysis of side effects, enabling us to identify newly emerging safety concerns and regularly assess the balance between the risks and benefits of using a pharmacological treatment.

    Safety data processing must be exact and of a high standard from a medical and scientific perspective to give accurate analysis and prompt corrective action, which in turn serves to safeguard the health of the patients and make it possible for the safe use of the drug.

    Why is it so important to ensure the highest degree of case processing quality?

    Case processing, a crucial pharmacovigilance activity, enables the transmission of substantial volumes of safety data across numerous stakeholders, such as patients, physicians, and responsible authorities. Processing a case involves the following steps:

    Case report presentation

    • Prioritization of case reports: duplicate check validation
    • Transmission of a medical evaluation to partners: quality assurance closure for data entry for archiving.
    • When processing cases, it is crucial to ensure the quality of the data.
    • Effective data analysis, scientific evaluation, and decision-making are dependent on the proper handling of case processing tasks, which in turn enables effective public health protection.
    • Observing regulations: To effectively protect the health of patients, safety data must be properly analyzed and used for benefit/risk evaluation and signal detection activities.

    Case processing common mistakes:

    Numerous quality problems are encountered by pharmacovigilance staff members who handle case processing activities. The most typical problem is:

    1. Insufficient reporting

    Contradictory data and coding errors signify an incomplete or inconsistent medical assessment.

    2. Incomplete report mistake 

    The most efficient way to deal with the issue of incomplete data is through routine training. 

    The quality assurance AE/SAE report is also included.

    3. Incorrect coding

    • The most important role of medical coding is to standardize and group disparate phrases into a standard parent category, which is necessary for efficient safety data analysis.
    • Medical coding is crucial for preventing spelling errors, inaccurate abbreviations, or non-standardized terms.
    • Coding mistakes can be avoided with a suitable and transparent source of data. Pharmacovigilance experts, however, occasionally get acronyms and information that are incorrect or unclear.
    • Congestion, of which the type (pulmonary, nasal, hepatic, sinus, etc.) is unclear,
    • Uncertainty about the sort of pain
    • Myocardial infarction (MI) or mitral incompetence (MI) are the two terms that are not entirely clear.
    • It is recommended to speak with the reporter personally to get clarification in such circumstances. The use of lower-level terminology might be permissible if the clarifications weren’t thorough.
    • If the clarifications are not exhaustive, lower-level terminology (LLT) should be used. The “MedDRA Points to Consider” page is also beneficial to review because it has a wealth of examples organized by type of coding issue.

    Narrative

    When crucial details from the case narrative are missing from the structured fields, it is a common type of error for the narrative to be incorrect.

    All information in the narrative must be accurately documented in the pertinent structured fields for pharmacovigilance professionals to promptly examine the cases and enable reliable data retrieval.

    How to Process a Quality Case

    Case processing is an essential task that forms the basis of pharmacovigilance decision-making. It enables the pharmacovigilance team to accurately analyze the safety data and take remedial actions promptly, ensuring that the drug benefits the patients in the best way possible.

    There are many strategies that can help to raise the standard of case processing, including:

    • Employees in clinical development, sales, medical information, legal, and quality control may require additional training.
    • Safety data collection forms that are easy to read and well-designed.
    • Random samples of patients are periodically examined.
    • All data entered into the database is subjected to quality control by a second individual.
    • Regular checking of a sample of instances taken randomly from the database. This can either be a thorough check or a check of the essential fields you’ve chosen.
    • Checking for deviations in KPIs and CAPAs.

                                                      Get the right chance to succeed in society and change things.

     A career in drug safety and pharmacovigilance affords you the chance to make a difference in people’s lives because of the recent increase in demand for pharmaceutical and drug safety specialists.

    Accredited courses in drug safety and pharmacovigilance are available at Sollers College.

  • Pharmacovigilance in Modern Healthcare

    Pharmacovigilance in Modern Healthcare

    The necessity for Pharmacovigilance is on the rise as the healthcare industry hailed for its achievements in science and technology. Pharmacovigilance is the science of healthcare providers producing and identifying medicines, and biologics is collected, monitored, researched, assessed, evaluated, etc. As the lifespan of a product unfolds, Pharmacovigilance plays an increasingly important role at each stage.

    As Pharmacovigilance has become a significant department in the healthcare business, every pharmaceutical company requires specialists who have received professional training in Pharmacovigilance. Several medical facilities, such as hospitals, medical clinics, and others, fall under this umbrella.

    Pharmacovigilance is critical to ensuring the safety of healthcare products during research and development. Some pharmaceuticals include hazardous substances that must be continuously monitored throughout production to prevent pollution of the environment and unintentional spills or leaks.

    A Set of Guidelines for Preventing Contamination in Industry

    Pharmacovigilance provides producers with various criteria to ensure that pharmaceutical facilities are free of contamination. As a result of these principles, the standard for deciding whether a substance is harmful or not may be concluded. Educating and training personnel in the safe management of these dangerous medications is also emphasized. Additionally, the rules urge businesses to set up appropriate locations for handling drugs and guarantee the safe evacuation of harmful material.

    FDA rules apply to all pharmaceutical products in the United States, including medications, biologics, and medical or diagnostic equipment (Food and Drug Administration). The FDA must approve a medicine or biologic’s clinical research and development to proceed safely. It includes filing accelerated reports for significant or unexpected adverse events or verified signals.

    Regulations Governing the Use of Diagnostic and Medical Devices

    Pharmacovigilance has established specific standards and rules to guarantee that new medical devices are safe to use, decreasing short-term and long-term diseases caused by exposure to harmful medications and their dangers.

    The closed system drug transfer device is more efficient, and workers are protected by this device’s leak-proof transfer of hazardous materials. Maintaining medication sterility while preventing the leakage of harmful substances into the surrounding environment is the primary goal of this device. Indeed, the amount of harmful medications in its vicinity has been lowered by this gadget.

    Pharmacovigilance is now much easier to do thanks to healthcare authorities’ rules and the availability of sophisticated safety equipment. Pharmacovigilance’s primary goal is to reduce the risk of dangerous medications by following these rules and appropriately managing safety equipment.

    Begin your career in Drug Safety & Pharmacovigilance today with Sollers. The program is designed to help you improve your clinical research skills at every step.

  • Big Data Analytics In Healthcare

    Big Data Analytics In Healthcare

    Data analytics are having a significant impact on the healthcare industry. As the world’s population lives longer on average, current treatment options face substantial hurdles in Clinical Data Science. In reality, healthcare analytics can minimize treatment costs, forecast epidemic breakouts, eliminate avoidable diseases and improve the overall quality of life.

     What Is Big Data In Healthcare?

     In healthcare, massive amounts of previously unmanageable data have been dubbed “big data.” It refers to the vast amounts of patient records and hospital performance data gathered through digital technologies previously uncontrollable by traditional technology.

     In healthcare, the use of big data analytics offers several benefits, including the potential to save lives. Big-style data refers to the massive amounts of data generated by digitalization, aggregated and evaluated by a particular technology. Use in healthcare might help avoid epidemics, treat sickness, or save expenses by using precise health data of a community (or a person).

     Treatment approaches have altered as people live longer, and many of these improvements have been driven by data. For this reason, doctors are always on the lookout for early warning symptoms of sickness to save money by treating it at its earliest possible stage rather than waiting until it is too late. Key performance indicators and healthcare data analytics may prevent illness rather than treat it. 

     Improvements in Staffing Predicted by Patients

     When it comes to implementing big data in healthcare, one of the most common issues shift managers confront is how many personnel to put on duty at any particular moment. If you hire too many people, you may end up paying for them in the long term. 

     EHRs (Electronic Health Records) 

    It’s the most common use of big data in the medical field. Digital records for each patient contain demographics, medical history, and allergies, as well as results of laboratory tests. Records are made available to public and private sector suppliers via secure information systems. Every patient’s medical history is made up of a single, editable file, allowing clinicians to make changes over time without the need for paperwork or the risk of data duplication.

    Alerting in Real-Time

    Real-time alerting is a crucial feature of other healthcare data analytics examples. Clinicians in hospitals can use Clinical Decision Support (CDS) software to help them make prescriptive judgments based on real-time data analysis.

    As a result, clinicians will examine this data in a socio-economic context and change their delivery tactics accordingly by accessing the general public’s health database. Institutions and care administrators will monitor and react to this vast data stream using advanced tools.

    Encouraging Patients to Participate

    Intelligent gadgets that record every step, heart rate, sleep pattern, etc., continuously are already popular with consumers and potential patients. Trackable data may be used to uncover possible health dangers hiding in the background.

     The Clinical Data Science Program will prepare you for the job market with the skills employers want. Obtain the skills employers want. This course aims to teach clinical supervisors how to apply effective learning methods in R, SAS, SQL, Machine Learning, and Tableau to clinical practice.

  • Challenges and Opportunities in Hiring in the Life Sciences

    Challenges and Opportunities in Hiring in the Life Sciences

    Life sciences organizations confront new difficulties in Clinical Trials, Drug Safety etc., and possibilities every year, but 2021 will be the year when they are front and center more than ever. According to the US Bureau of Labor Statistics, professions in the life, physical, and social sciences will expand by 7% by 2028. It will be quicker than the national average for all other vocations. Within the following decade, this would imply the creation of around 97400 new employment.

    The COVID-19 epidemic has also shifted the job landscape by emphasizing the importance of the biological sciences industry.

    Industry expansion is vital. Because of the pandemic’s need, there is a fierce and considerably more demand for talent than ever before. Employers have faced issues as a result of a rising supply and demand mismatch for trained individuals. Candidates with experience in areas such as healthcare, biotechnology, and pharmaceuticals will be in great demand. Companies would have to undergo a more extended recruitment procedure to fill life sciences, especially in specialist areas.

    The need for technological skills is growing. With the convergence of technology and life sciences, there has been a greater emphasis on recruiting personnel with the skills to offer tech-enabled solutions. Biotech, data analysis, and digital product management will be in high demand in 2021 and beyond. Companies will remain ahead of the curve in a continuously changing industry.

    Remote positions are becoming more prevalent. The pandemic has caused a shift in the rise of small labor in a variety of industries. Many conventional jobs in the life sciences industry have gone online and will continue to be distant in the future. The need for remote positions for healthcare practitioners such as physicians, nurses, and other clinicians has increased as telehealth services have been more widely adopted.

    Biopharma and life sciences businesses are now competing with technology companies for specialized sector personnel, such as computational biologists and bioinformaticians, in addition to seeking the same talent pool as other industrial sectors for general digital skills. 

    Are you prepared to take chances on applicants with less experience but a desire for innovation?

    That is very dependent on the function. In some instances, especially in specialized areas, you cannot afford to take the risk or devote the time to train individuals up. In other cases, hiring for potential and enthusiasm makes excellent sense. 

    Sollers provides certificate programs in various life science fields such as Clinical Research, Clinical Data Science and Drug Safety & Pharmacovigilance. 

×